Looks like you’re on the UK site. Choose another location to see content specific to your location
AstraZeneca’s COPD drug Daxas turned down by NICE for NHS use
AstraZeneca's chronic obstructive pulmonary disease (COPD) drug Daxas has been turned down by the National Institute for Health and Care Excellence (NICE) for use on the NHS.
PharmaTimes reports that Daxas, the branded name for roflumilast, has not been recommended for use to treat the condition in draft guidance published by the healthcare body.
Trials had been underway to prove Daxas to be an effective oral treatment for adults with chronic forms of bronchitis when combined with current bronchodilator treatment options.
Daxas is intended to target the cells and biological mediators that play a key role in the development of COPD as a result of its function as a long-acting selective phosphodiesterase-4 enzyme inhibitor.
However, despite the results attributed to the drug in initial trials, NICE has deemed Daxas too expensive at this current time to be viable for widespread use on the NHS, as it is not seen as a cost-effective use for the health service's resources at present.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
Image: dolgachov via iStock
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard